TITLE

Do implementation issues influence the effectiveness of medications? The case of nicotine replacement therapy and bupropion in UK Stop Smoking Services

AUTHOR(S)
McEwen, Andy; West, Robert
PUB. DATE
January 2009
SOURCE
BMC Public Health;2009, Vol. 9 Issue 1, p28
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Effective pharmacotherapies are available for smoking cessation but their efficacy is established through randomised controlled trials where the medication is supplied direct to subjects. In health care settings patient access to medicines is often less direct. The process for obtaining supplies of nicotine replacement therapy (NRT) is relatively easy for smokers attending National Health Service (NHS) Stop Smoking Services in the UK, whilst this is not necessarily the case for those wishing to using prescription only medicines (e.g. bupropion and varenicline). This study was a direct comparison of the short-term validated abstinence rates of NRT and bupropion in a clinical setting. Methods: Data were routinely collected from 2626 clients setting a quit date (82% of those registering) with two London NHS Stop Smoking Services that offered behavioural support combined with pharmacotherapy (NRT and bupropion). Results: Contrary to what would be expected from multiple randomised controlled trials, the CO-validated 3-4 week abstinence rate in clients using NRT was higher than for bupropion (42% versus 34%, p = .003). This difference persisted even when controlling for smoking characteristics, demographic variables and treatment variables 1.40 (95% CI = 1.08 - 1.83). Conclusion: Given that the level of behavioural support received by clients on each medication was identical, the most plausible explanation for the difference in effectiveness between NRT and bupropion perhaps lies with how clients of the Stop Smoking Services obtained their medications. Obtaining NRT was relatively easy for clients throughout the study period whilst this was not the case for bupropion. This study suggests that implementation issues and/or self-selection may influence the effectiveness of medications in health care, as opposed to research, settings.
ACCESSION #
51511493

 

Related Articles

  • PP147 Olaratumab With Doxorubicin For Advanced Soft Tissue Sarcoma. Tikhonova, Irina; Jones-Hughes, Tracey; Dunham, James; Warren, Fiona; Robinson, Sophie; Hoyle, Martin // International Journal of Technology Assessment in Health Care;2018 Supplement, Vol. 34, p123 

    Introduction: The National Institute for Health and Care Excellence (NICE) invited the manufacturer of olaratumab (Lartruvo®), Eli Lilly & Company Limited, to submit evidence for the clinical and cost effectiveness of this drug, in combination with doxorubicin, for advanced soft tissue...

  • Is Monotherapy for Febrile Neutropenia Still a Viable Alternative? Ramphal, Reuben // Clinical Infectious Diseases;9/1/1999, Vol. 29 Issue 3, p508 

    Discusses the viability of monotherapy for febrile neutropenia. Background on monotherapy and the basis of its being controversial; Comparison of monotherapy with combination therapy; Why monotherapy should be re-evaluated.

  • Amoxicillin versus Sparfloxacin in the Treatment Presumed Pneumococcal Pneumonia. Johnson, James R. // Clinical Infectious Diseases;1/1/2000, Vol. 30 Issue 1, p234 

    Comments on an article on the use of amoxillin versus sparfloxacin for treating presumed pneumococcal pneumonia published in a 1998 issue of the 'Clinical Infectious Diseases' journal. Flaws in the conclusions reached by the authors of this article regarding the drug regimens; Flaws in their...

  • Reply. Young, Lowell S. // Clinical Infectious Diseases;1/1/2000, Vol. 30 Issue 1, p2351 

    Responds to James R. Johnson's comments on the use of amoxicillin versus sparfloxacin for treating pneumococcal pneumonia published in a 2000 issue of the 'Clinical Infectious Diseases' journal. Involvement of most medical specialties in the issue of pharmaceutical industry sponsorship; Fact of...

  • Vancomycin-Induced Neutropenia Resolves after Substitution with Teicoplanin. Sanche, Stephen E.; Dust, William N.; Shevchuk, Yvonne M. // Clinical Infectious Diseases;9/1/2000, Vol. 31 Issue 3, p824 

    Reports the potential of the compound teicoplanin which is structurally related to the antibiotic vancomycin in resolving the neutropenia effect associated with prolonged vancomycin therapy. Therapeutic options for individuals who have not completed an adequate treatment course at the time of...

  • Why the AUC/MIC Ratio Should Not Be Used to Predict the Effects of b -Lactams. Mouton, Johan W. // Clinical Infectious Diseases;7/15/2002, Vol. 35 Issue 2, p209 

    Comments on an article about pharmacokinetic and pharmacodynamic (PK/PD) relationships. Application of PK/PD indices for predicting the effect of combination therapy; Influence of antibiotic area under the curve on the determination of drug effects; Analysis of drug effects.

  • Optimising antiemesis in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high dose metoclopramide in emesis induced by cisplatin. Warrington, Pamela S.; Allan, Simon G.; Cornbleet, Michael A.; Macpherson, Janet S.; Smyth, John F.; Leonard, Robert C.F. // British Medical Journal (Clinical Research Edition);11/22/1986, Vol. 293 Issue 6558, p1334 

    Examines the efficacy of metoclopramide in emesis induced by cisplatin in cancer chemotherapy. Evaluation of continuous and intermittent infusion of metoclopramide; Importance of gastrointestinal sequelae of chemotherapy; Reduction of nausea on the visual analogue scale.

  • Can Valaciclovir Suppress Recurrent Genital HSV? MILLER, KARL // American Family Physician;2/15/1999, Vol. 59 Issue 4, p999 

    Discusses the study `Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study,' by M. Reitano et al which appeared in the September 1998 issue of the Journal of Infectious Diseases. Methodology; Selection of patients for study;...

  • New Treatment Regimen Is Effective in Patients with Heart Failure. Rose, Verna L. // American Family Physician;8/1/1999, Vol. 60 Issue 2, p600 

    Highlights the Randomized Aldactone Evaluation Study focusing on the effectiveness of spironolactone (Aldactone) being added to the standard treatment regimens in reducing total mortality in patients with severe heart failure. Methodology; Results; Conclusion; Implications.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics